Comparison of all renal replacement therapy modalities in terms of COVID-19 infection rate & mortality in the COVID-19 pandemic and importance of home therapies.

IF 1.5 4区医学 Q3 HEMATOLOGY

Therapeutic Apheresis and Dialysis Pub Date : 2023-06-01 DOI:10.1111/1744-9987.13930

Serdar Kahvecioglu, Nurhan Bilen, Huseyin Celik, Cuma Bulent Gul, Mehmet Usta, Nimet Aktaş, Yusuf Bilen

{"title":"Comparison of all renal replacement therapy modalities in terms of COVID-19 infection rate & mortality in the COVID-19 pandemic and importance of home therapies.","authors":"Serdar Kahvecioglu, Nurhan Bilen, Huseyin Celik, Cuma Bulent Gul, Mehmet Usta, Nimet Aktaş, Yusuf Bilen","doi":"10.1111/1744-9987.13930","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to compare the infection rate and infection-related mortality among all renal replacement therapies during the COVID-19 pandemics.Methods: One thousand three hundred thirty-six end-stage renal disease (ESRD) patients who had applied for renal replacement therapy between March 2020 and January 2021 were included in the study. COVID-19 infection and mortality rates were compared between patient groups.Results: The COVID-19 infection rate in the whole study group was 13.12% (n: 178). The highest infection rate was in the center hemodialysis, 16.33% (n: 139). There was no COVID-19 infection in home hemodialysis (HHD). Mortality rate was 2.87% (n: 39) in the whole cohort and 3.87% (n: 33) in center hemodialysis (CHD), 1.47% (n:5) in kidney transplant (Tx), and 0.81% (n: 1) in the peritoneal dialysis (PD) group. COVID-19 infection rate of home replacement therapy (HRT) (n: 39) patients was significantly lower than CHD (n: 139) (p < 0.001).Conclusion: The COVID-19 infection rate and mortality were significantly lower than those of CHD in all home-based modalities subgroups.","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538799/pdf/TAP-9999-0.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Apheresis and Dialysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1744-9987.13930","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to compare the infection rate and infection-related mortality among all renal replacement therapies during the COVID-19 pandemics.

Methods: One thousand three hundred thirty-six end-stage renal disease (ESRD) patients who had applied for renal replacement therapy between March 2020 and January 2021 were included in the study. COVID-19 infection and mortality rates were compared between patient groups.

Results: The COVID-19 infection rate in the whole study group was 13.12% (n: 178). The highest infection rate was in the center hemodialysis, 16.33% (n: 139). There was no COVID-19 infection in home hemodialysis (HHD). Mortality rate was 2.87% (n: 39) in the whole cohort and 3.87% (n: 33) in center hemodialysis (CHD), 1.47% (n:5) in kidney transplant (Tx), and 0.81% (n: 1) in the peritoneal dialysis (PD) group. COVID-19 infection rate of home replacement therapy (HRT) (n: 39) patients was significantly lower than CHD (n: 139) (p < 0.001).

Conclusion: The COVID-19 infection rate and mortality were significantly lower than those of CHD in all home-based modalities subgroups.

查看原文本刊更多论文

所有肾脏替代治疗方式在COVID-19大流行中COVID-19感染率和死亡率的比较以及家庭治疗的重要性

背景:本研究旨在比较COVID-19大流行期间所有肾脏替代疗法的感染率和感染相关死亡率。方法:在2020年3月至2021年1月期间申请肾脏替代治疗的1336例终末期肾病(ESRD)患者纳入研究。比较两组患者COVID-19感染率和死亡率。结果:整个研究组的COVID-19感染率为13.12%(178例)。中心血透部感染率最高，为16.33%(139例)。家庭血液透析组无COVID-19感染。全队列死亡率为2.87% (n: 39)，中心血液透析(CHD)组死亡率为3.87% (n: 33)，肾移植(Tx)组死亡率为1.47% (n:5)，腹膜透析(PD)组死亡率为0.81% (n: 1)。家庭替代疗法(HRT)患者的COVID-19感染率(n: 39)显著低于冠心病患者(n: 139) (p结论:家庭替代疗法各亚组患者的COVID-19感染率和死亡率均显著低于冠心病患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Apheresis and Dialysis 医学-泌尿学与肾脏学

CiteScore

3.00

自引率

10.50%

发文量

166

审稿时长

6-12 weeks

期刊介绍： Therapeutic Apheresis and Dialysis is the official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis and the Japanese Society for Dialysis Therapy. The Journal publishes original articles, editorial comments, review articles, case reports, meeting abstracts and Communications information on apheresis and dialysis technologies and treatments.